• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hemostemix Inc (OP:HMTXF)

0.0577 -0.0050 (-7.97%)
Streaming Delayed Price Updated: 11:44 AM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,979
Open 0.0576
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0627
Today's Range 0.0576 - 0.0577
52wk Range 0.0500 - 0.2850
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
December 31, 2025
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"),... 
Via Newsfile
News headline image
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
December 23, 2025
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),... 
Via Newsfile

Performance

YTD
-8.0%
-8.0%
1 Month
-8.4%
-8.4%
3 Month
-26.3%
-26.3%
6 Month
-46.6%
-46.6%
1 Year
-15.1%
-15.1%

More News

Read More
News headline image
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
December 11, 2025
Via Newsfile
News headline image
Hemostemix Grants Stock Options
December 11, 2025
Via Newsfile
News headline image
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
December 10, 2025
Via Newsfile
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
September 18, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
September 16, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
March 14, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
March 12, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
September 27, 2022
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
September 20, 2022
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
September 16, 2022
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
September 15, 2022
Via Newsfile
Topics Intellectual Property
News headline image
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
September 14, 2022
Via Newsfile
News headline image
Hemostemix Announces Its Presentation to the Emerging Growth Conference
September 14, 2022
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
September 13, 2022
Via Newsfile
News headline image
Hemostemix Announces Closing of $2,750,000
April 26, 2022
Via IssueWire
Topics Intellectual Property
News headline image
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
April 13, 2022
Via IssueWire
Topics Intellectual Property Lawsuit
News headline image
Your Fountain of Youth Trademarked by Hemostemix Inc.
March 03, 2022
Via IssueWire
Topics Intellectual Property
News headline image
Hemostemix Announces Closing of UNIT Private Placement
March 03, 2022
Via IssueWire
News headline image
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday ↗
December 14, 2021
Via Benzinga
News headline image
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
September 14, 2021
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
July 06, 2021
Via Newsfile
Topics Economy Intellectual Property
News headline image
Peter Lacey Increases His Investment in Hemostemix Inc.
June 21, 2021
Via Newsfile
Topics Intellectual Property
News headline image
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
June 11, 2021
Via Newsfile
Topics Economy Intellectual Property

Frequently Asked Questions

Is Hemostemix Inc publicly traded?
Yes, Hemostemix Inc is publicly traded.
What exchange does Hemostemix Inc trade on?
Hemostemix Inc trades on the OTC Traded
What is the ticker symbol for Hemostemix Inc?
The ticker symbol for Hemostemix Inc is HMTXF on the OTC Traded
What is the current price of Hemostemix Inc?
The current price of Hemostemix Inc is 0.0577
When was Hemostemix Inc last traded?
The last trade of Hemostemix Inc was at 01/05/26 11:44 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap